Exploring liver fibrosis biomarkers in non-alcoholic fatty liver disease (NAFLD)

Not Applicable

• Conditions: AFLD/NASH

• Registration Number: JPRN-UMIN000036576
• Lead Sponsor: ippon Medical School Chiba Hokusoh Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-04-23
• Study Completion: 2022-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Exclusion criteria included 1) daily alcohol consumption >30 g for males and >20 g for females; 2) other chronic liver diseases, such as viral hepatitis B or C, autoimmune hepatitis, Wilson disease, and hemochromatosis; 3) secondary causes of steatosis, such as drug-induced fatty liver disease, total parenteral nutrition, and inborn errors of metabolism.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the efficacy of liver fibrosis biomarkers in patients with nonalcoholic fatty liver disease

Secondary Outcome Measures

Name	Time	Method
Effect of liver fibrosis on arteriosclerosis